BioNTech to pay $467M in settlement agreement with University of Pennsylvania
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Here are Morgan Stanley’s key oncology catalysts for 2025
Last year, Moderna ( NASDAQ: MRNA) made headlines with its individualized mRNA cancer vaccine mRNA-4157 (V940), developed ...
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...
devdiscourse5h
Global Health Developments: From Cancer Breakthroughs to Bird Flu Mutations
Recent health news includes the FDA's approval of an injectable version of Opdivo, a revived lawsuit against Novartis for ...
BioNTech SE ADR falls Thursday, underperforms market
The ADR's fall snapped a three-day winning streak.
Reuters on MSN15d
US FDA lifts partial clinical hold on BioNTech cancer drug study
Dec 13 (Reuters) - BioNTech SE (22UAy.DE), opens new tab said on Friday it has been informed by its partner OncoC4 that the ...
devdiscourse13h
Regulatory Developments in Health: From Cancer Drugs to Vaccine Royalties
Recent developments in health include the FDA approving an injectable version of Opdivo, a revived lawsuit against Novartis ...